Check out our March 2026 #dementia newsletter, with updates from across Europe and beyond!
bit.ly/AE-newslette...

“An early diagnosis can help people and families access the right support sooner.”

For #BrainAwarenessWeek, discover how FluiDx-AD is working on saliva- and blood-based biomarker tests for Alzheimer’s disease.

#BAW2026 #BrainAwarenessWeek2026

For Brain Awareness Week, why does early diagnosis matter?

“Being able to obtain an early diagnosis would enable families, and carer members in particular, to plan ahead for lifestyle changes, consider support that will inevitably be needed and hopefully avoid too many crises.”
#BrainAwarenessWeek

Our first #FluiDxAD newsletter is out
@fluidx-ad.bsky.social, funded by Horizon Europe, is developing minimally invasive saliva- and blood-based tests to support earlier diagnosis & management of Alzheimer’s disease.
Read: mailchi.mp/42c58952021c...
Subscribe: eepurl.com/i-L--U
#BrainAwarenessWeek

Interview with Vebjørn Anderson about the FluiDx-AD project Welcome to the FluiDx-AD project! FluiDx-AD is a collaborative Horizon Europe-funded project aimed at improving Alzheimer’s disease diagnosis and management.…

FluiDx-AD is a Horizon Europe project developing saliva- & blood-based tests for earlier Alzheimer’s disease diagnosis and better access to next-generation treatments.
Watch our interview with Vebjørn Andersson from Oslo University Hospital:
vimeo.com/1170223264?s...
#BrainAwarenessWeek2026 #BAW2026

FluiDx-AD - A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of AD Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither…

It's #BrainAwarenessWeek!
By developing innovative saliva- and blood-based diagnostic tests, we strive to improve early detection, facilitate access to next-generation treatments and to enhance the quality of life for millions affected by #Alzheimer’s disease.
vimeo.com/1058971988?f...

French Government leads on non-paper to reinstate operating grants for health NGOs The French Government has led on the submission of a non-paper, along with 12 other Member States, calling on the European Commission to reconsider it

France supported by 9 other Member States is asking the European Commission to reintroduce operating grants to the EU health programme
The abolition of these grants has impacted the ability of associations to give a voice to patients in EU policies
#EU4Health
www.alzheimer-europe.org/news/french-...

📰 Our February newsletter is out today, with #dementia news from across Europe and beyond... !

Download it, here: bit.ly/AE-newslette...

And just in case you missed the January edition, check it out here: bit.ly/AE-newslette...

Have a read of the latest @alzheimereurope.bsky.social newsletter, covering how the members of #H2020 @fluidx-ad.bsky.social project's Advisory Board participated in a consultation about findings from a systematic review & its communication to the public:
www.alzheimer-europe.org/sites/defaul...

Members of the @fluidx-ad.bsky.social Advisory Board consult about findings from systematic review about the effects of diagnosing Alzheimer's disease via fluid-based biomarker tests.
Thanks for their feedback & the engaged discussion!

www.fluidx-ad.eu/fluidx-ad-co...
@alzheimereurope.bsky.social

Members of the @fluidx-ad.bsky.social projects' Advisory Board held their first online meeting.
FluiDx-AD is a collaborative project aimed at improving Alzheimer’s disease diagnosis & management through the development of innovative saliva and blood-based tests.
www.fluidx-ad.eu/members-of-t...

Yesterday, project partners Faye Forsyth & @chrisbintener.bsky.social met with members of @alzheimereurope.bsky.social European Working Group of People with Dementia to discuss how to implement feedback on a saliva sample collection procedure to screen for #Alzheimer’s disease biomarkers. #EWGPWD

Today, Faye Forsyth & I met Praveen Sharma to discuss feedback from EWGPWD and EDCWG on a device to detect Alzheimer’s disease biomarkers in saliva.
Next week we’ll focus on how to communicate test results with potential future users: fluidx-ad.eu

Have a read of @alzheimereurope.bsky.social newsletter, featuring the first #H2020 @fluidx-ad.bsky.social General Assembly & a consultation with the European Working Group of People with Dementia & European Dementia Carers Working Group on a saliva prototype for Alzheimer’s disease biomarkers.

HemoDx, is developing a saliva collection device that could enable cheaper and easier screening for #Alzheimer’s disease.

Together with @alzheimereurope.bsky.social, people affected by dementia provided feedback through structured Public Involvement consultations.
www.fluidx-ad.eu/fluidx-ad-co...

The @fluidx-ad.bsky.social consortium met in Bologna to review progress and plan next steps in developing saliva, plasma and blood tests to improve early diagnosis & management of #Alzheimer’s disease.
Read more: www.fluidx-ad.eu/fluidx-ad-co...

Ahead of @alzheimereurope.bsky.social #35AEC Bologna: members of the European Working Group of People with Dementia & the European Dementia Carers Working Group are consulting on @fluidx-ad.bsky.social prototype saliva-based screening tests for Alzheimer’s disease risk indication.
www.fluidx-ad.eu

Anti-amyloid therapies cause ARIA in a subset of patients. We are working on blood-based biomarkers & a whole-blood ex vivo assay to help identify who may benefit and who may be at higher risk, supporting eligibility assessment & monitoring.
www.fluidx-ad.eu #WorldAlzMonth #WAM2025

Accessible, low-burden testing matters. FluiDx-AD is working towards validation of saliva and plasma biomarkers as well as automated workflows that fit routine clinics, with documentation to support future regulatory steps. www.fluidx-ad.eu
#WorldAlzMonth #WAM2025

“Low-cost & simple” matters when you are waiting for answers. Earlier diagnosis helps people plan, seek support, and know what to expect. We aim to evaluate a three-test approach using saliva & blood biomarkers to support earlier, reliable decisions.
#WorldAlzMonth #WAM2025 www.fluidx-ad.eu

Early answers open access to support. FluiDx-AD aims to develop and validate three complementary tests: saliva risk indication, plasma confirmation, and a whole blood ex-vivo assay for ARIA risk to guide therapy decisions. #WorldAlzMonth #WAM2025 #WorldAlzheimersMonth
www.fluidx-ad.eu

Early, reliable answers help families plan.
FluiDx-AD aims to develop & validate three complementary, minimally invasive tests (saliva-based risk indication, plasma-based confirmatory biomarkers, & an assay for ARIA assessment). www.fluidx-ad.eu
#WorldAlzMonth #WAM2025

In FluiDx-AD, we aim to develop & validate a trio of saliva- and blood-based tests to support earlier detection, precise confirmation, and ARIA risk assessment for therapy decisions. More information: www.fluidx-ad.eu
#WorldAlzheimersMonth #WAM2025 #WorldAlzMonth

People may have to wait far too long for an Alzheimer’s disease diagnosis.
FluiDx-AD aims to shorten diagnostic pathways by developing & standardising fluid-based biomarker tests. linktr.ee/FluiDx_AD
#WorldAlzheimersMonth #WAM2025 #WorldAlzMonth

FluiDx-AD - A novel test trio to detect peptide biomarkers in saliva and blood for enhanced diagnosis and management of AD Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither…

🧠On #WorldBrainDay #WBD2025 we highlight FluiDx-AD, improving early Alzheimer’s diagnosis with saliva & blood-based tests.
Led by Oslo University Hospital & Pre Diagnostics, with Alzheimer Europe leading on communication & Public Involvement.
🎥 vimeo.com/1058971988
🔗 linktr.ee/FluiDx_AD

The AI-Mind project builds AI tools to scan brain connectivity and predict dementia risk, giving clinicians earlier insight.
Horizon Europe spin-off @fluidx-ad.bsky.social proves the impact. Details in Alzheimer Europe's Dementia in Europe Magazine supplement
www.alzheimer-europe.org/sites/defaul...

Survey Study Aims to Assess Germany’s Readiness for Early Alzheimer Diagnosis Using Biomarkers A new survey study will assess how well German memory clinics and specialists are equipped to provide early and accurate Alzheimer diagnoses using biomarker-based methods.

Survey Study Aims to Assess Germany’s Readiness for Early #Alzheimer Diagnosis Using Biomarkers #ADPD2025

👉 www.neurologylive.com/view/survey-...

At-home saliva test for prostate cancer better than blood test, study suggests Researchers say ‘relatively simple, inexpensive’ means of assessing genetic risk offers hope of better screening

A new study shows a saliva test outperforms current blood tests in predicting prostate cancer risk.
@fluidx-ad.bsky.social aims to do the same for #Alzheimer’s, with SalivaDx-AD enabling easy at-home risk detection.

www.alzheimer-europe.org/our-work/cur...

www.theguardian.com/society/2025...

El proyecto FluiDx-AD busca mejorar el diagnóstico del Alzheimer El proyecto FluiDx-AD busca pruebas clínicas para mejorar el diagnóstico precoz y la gestión de la enfermedad de Alzheimer

A big thank you to @geriatricarea.bsky.social, who shared our press release about the launch of @fluidx-ad.bsky.social in their news coverage!
Link (in Spanish!) below ⏬
www.geriatricarea.com/2025/04/03/e...

The new Alzheimer Europe Dementia in Europe Magazine features an interview with our Scientific Coordinator Erik Christensen, putting a spotlight on the novel test trio to detect peptide biomarkers for enhanced diagnosis & management of #Alzheimer's disease ⤵️
www.alzheimer-europe.org/sites/defaul...